Systemic sclerosis & Raynaud's
Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome
Authors' conclusion
Reactivity of functionally active anti-AT1R antibodies was not influenced by aSCT, while anti-topo-I antibodies decreased after aSCT. The fact that anti-topo-I antibodies inhibited enzyme function in all instances supports the hypothesis of a pathogenetic role of the topo-I antigen/antibody-system in SSc. High anti-topo-I reactivity before aSCT was associated with an unfavourable, presence of stimulatory anti-AT1R antibodies with a favourable course after aSCT.
Study context
- Population
- SSc patients in whom autologous stem cell transplantation (aSCT) was performed
- Participants
- 43 patients
- Exposure
- Favourable outcome after aSCT vs no response or relapse
- Group 1n = 31reference
- Group 2n = 12
- Outcome
- Antibodies before aSCT (ELISA, LA) and change after aSCT
- Follow-up
- Before and after aSCT (4-217 months, median 28 months)
Main finding
As reported in the abstract
Anti-topo-I antibodies (ELISA) before aSCT
70%
Anti-AT1R antibodies (ELISA) before aSCT
51%
Stimulatory anti-AT1R antibodies (luminometric assay (LA))
40%
Inhibitory anti-AT1R antibodies (LA)
12%
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →